Hepatocellular Adenoma Workup
- Author: Sandeep Mukherjee, MB, BCh, MPH, FRCPC; Chief Editor: Julian Katz, MD more...
Laboratory Studies
- Serologically, hepatocellular adenomas are a diagnosis of exclusion. No specific serologic studies exist.
- Serum aminotransferase (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]) levels are mildly elevated in approximately 50% of patients, likely due to the mass effect of the tumor.
- Serum alpha-fetoprotein (AFP) levels are within the reference range in patients with hepatocellular adenoma. Elevations are noted in 50% of hepatocellular carcinoma (HCC) cases. Thus, finding an elevated AFP represents either a primary carcinoma or an adenoma that has undergone malignant transformation. An AFP level within the reference range does not eliminate HCC from the differential diagnosis.
- Elevated carcinoembryonic antigen (CEA) levels suggest metastasis from the colon.
- Serologies for amebiasis and echinococcus should be considered if the lesion appears cystic.
Imaging Studies
- Findings on imaging studies in cases of hepatocellular adenomas generally are nondiagnostic because the mass often is solitary and well demarcated. Distinguishing characteristics generally are absent. Ultrasound and CT imaging are more specific if intralesional hemorrhage is noted.
- Ultrasound
- A nonspecific finding reveals a hypoechoic lesion, which usually is subcapsular (7% pedunculated), well circumscribed, ranges from 2-20 cm, and is located predominantly in the right lobe of the liver.
- Doppler flow patterns in hepatocellular adenomas are venous, as compared to the arterial pattern noted in FNH.
- Computed tomography imaging
- A nonspecific, well-circumscribed mass that has a low density on noncontrast and a marked centripetal pattern of enhancement on arterial phase
- The lesion can have a central necrotic area or calcifications.
- Most adenomas are encapsulated on CT scan.
- Magnetic resonance imaging (MRI)
- Variable appearance due to the presence or absence of hemorrhage
- Hyperintense heterogeneous signals on T1- and T2-weighted imaging often due to lipids contained within the lesion[17]
- Hemorrhagic hepatocellular adenomas may also have hyperintense T1 imaging with subcapsular hemosiderin rings in 30% of patients.
- Kupffer cell–specific MRI agents (superparamagnetic iron oxides [SPIO] and ultrasmall superparamagnetic iron oxides [USPIO]) can be administered during the scan. They show no uptake due to a lack of endothelial-reticular cells.
- Manganese–dipyridoxal diphosphate (DPDP), gadolinium, or gadobenate dimeglumine (Gd-BOPTA) can be administered during the scan. These show strong uptake due to the presence of hepatocytes. MRI with contrast can differentiate hepatocellular adenoma from FNH in 70% of cases.[18]
- Unfortunately, HCC also has a predominance of hepatocytes, which makes these agents unable to differentiate between hepatocellular adenomas and HCC.
- Nuclear scans
- Hepatocellular adenomas appear as cold nodules on technetium-99m (99m Tc) sulfur colloid scans, which distinguishes them from FNH, which typically shows normal or increased colloid uptake.
- This is due to the altered blood flow through the lesions and the lack of phagocytic activity of Kupffer cells.
- Arteriography
- This imaging modality is rarely performed and has been substituted by CT or MR angiography in most centers.
- Well-defined, round or ovoid, hypervascular mass with hepatic arterial branches entering from the periphery
- Vessels within the mass are tortuous and of varying calibers with flow moving centrally from the periphery.
- Avascular areas and intralesional hematomas are indicators of hepatocellular adenomas.
Other Tests
Although hepatocellular adenomas may transform into HCC, the AFP is an insensitive test for HCC screening, yet few other tests are available. Zucman-Rossi et al classified 96 hepatocellular adenomas by sequencing the genes coding for hepatocyte nuclear factor-1 alpha (HNF1 alpha) and beta-catenin.[19] The investigators reported that HCC is found in 46% of beta-catenin-mutated tumors, whereas they are rarely found in HNF1 alpha tumors or tumors which lack beta-catenin or HNF1 alpha.
Tumor cell expression patterns of E-cadherin and matrix metalloproteinases -1,-2,-7 and -9 were studied in a variety of liver tumors and controls by Tretiakova et al.[20] The investigators reported that hepatocellular adenoma was characterized by an absence of matrix metalloproteinase-7 expression, whereas HCC without cirrhosis had low metalloproteinase-9 expression.
Glycipan-3 (GPC3) is a cell surface glycoprotein recently to be overexpressed in HCCs. Wang reported that GPC3 staining was not present in all 110 cases of benign liver tumors in their study, yet the staining was positive in 75.7% of HCCs.[21]
Agrin is a proteoglycan component of bile duct and vascular basement membranes of the liver and is deposited in microscopic blood vessels of HCC. Tatrai et al reported that the combination of immunohistochemical staining for agrin and CD34 was helpful for differentiating HCC from benign lesions when the diagnosis was equivocal.[22] In addition, agrin appeared to be more sensitive than GPC-3, as agrin is diffusely deposited in all malignant lesions, whereas GPC-3 may only be present in a few cells.
Ahmad reported that a combination of cytokeratin 7 and 9 with neuronal cell adhesion molecule immunostains were very helpful for differentiating normal liver tissue from tumors and also for differentiating hepatocellular adenomas from FNH.[23]
Procedures
- Results of histologic evaluation with a liver biopsy are nondiagnostic and insensitive because the mass is comprised of normal-appearing hepatocytes.
- Resection and evaluation may be required as the most specific way to confirm diagnosis.
Histologic Findings
Upon gross examination, hepatocellular adenomas appear as sharply circumscribed, light brown to yellow tumors that are soft in consistency and are often encapsulated. Although these lesions are usually solitary, hepatocellular adenomas may be multiple, with sizes ranging from 1 to 30 cm, although most are between 8 and 15 cm. Adenomas tend to be larger in women on OCPs. They also occur more frequently in the right lobe and are usually subcapsular, although pedunculated adenomas have also been described.
In a microscopic examination, the hallmark of adenomas is the normal appearance of the hepatocytes. These are arranged in sheets and have no malignant features. These cells tend to be larger than normal hepatocytes, and their cytoplasm often contains fat or glycogen. (Their cytoplasm may appear relatively pale due to abundant glycogen stores when compared with normal hepatocytes). Generally, few, if any, portal tracts are present, and no central veins or bile ducts should be present.[24] However, Bisceglia et al reported that subtypes of HAs may have CK7 positive ductules and are called hepatocellular adenoma with ductal/ductular differentiation.[25]
Peliosis hepatis may occasionally be seen, and Kupffer cells are reduced in number or absent.[26] Vessels, when observed, tend to have thickened walls. Areas of thrombosis and infarction may be observed. Most hepatocellular adenomas contain a variable degree of microscopic collections of fat. Differentiation from a high-grade HCC can be difficult, if not impossible. Adenomas tend to lack malignant-appearing mitotic structures, the cell plates are generally only 2 cells thick, and no cellular infiltration (invasion) into the capsule or surrounding liver parenchyma occurs. Unfortunately, these features may also be absent in HCC, especially if it is well differentiated.
Hypervascularity is present upon the surface of the lesion. Because adenomas contain no portal vein branches, their blood supply is entirely arterial. The tendency for these lesions to bleed may be related to poor connective tissue support and their increased vasculature, which is made up of thin-walled, dilated sinusoids carrying blood at arterial pressure.
Edmonson HA. Tumors of the liver and biliary tract. Fascicle 25. In: Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 1958.
Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med. Feb 26 1976;294(9):470-2. [Medline].
Baum JK, Bookstein JJ, Holtz F. Possible association between benign hepatomas and oral contraceptives. Lancet. Oct 27 1973;2(7835):926-9. [Medline].
Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology. Aug 1977;DA - 19770825(2):386-94. [Medline].
Rooks JB, Ory HW, Ishak KG. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. Aug 17 1979;242(7):644-8. [Medline].
Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology. Dec 1995;22(6):1674-81. [Medline].
Edmonson HA, Reynolds TB, Henderson B,et al. Regression of liver cell adenomas associated with oral contraceptives. Ann Int Med. 1977;86(2):180-182.
Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. Mar 1997;24(3):276-9. [Medline].
Volmar KE, Burchette JL, Creager AJ. Hepatic adenomatosis in glycogen storage disease type Ia: report of a case with unusual histology. Arch Pathol Lab Med. Oct 2003;127(10):e402-5. [Medline].
Grazioli L, Federle MP, Ichikawa T, et al. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology. Aug 2000;216(2):395-402. [Medline].
Arsenault TM, Johnson CD, Gorman B, Burgart LJ. Hepatic adenomatosis. Mayo Clin Proc. May 1996;71(5):478-80. [Medline].
Masood S, West AB, Barwick KW. Expression of steroid hormone receptors in benign hepatic tumors. An immunocytochemical study. Arch Pathol Lab Med. Dec 1992;116(12):1355-9. [Medline].
Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. Jan 2008;48(1):163-70. [Medline].
Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol. May 21 2007;13(19):2649-54. [Medline].
Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. Aug 2009;50(2):481-9. [Medline].
Reznik Y, Dao T, Coutant R, et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab. Mar 2004;89(3):1476-80. [Medline].
Laumonier H, Bioulac-Sage P, Laurent C, et al. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology. Sep 2008;48(3):808-18. [Medline].
Assy N, Nasser G, Djibre A, et al. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol. Jul 14 2009;15(26):3217-27. [Medline].
Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. Mar 2006;43(3):515-24. [Medline].
Tretiakova MS, Hart J, Shabani-Rad MT, Zhang J, Gao ZH. Distinction of hepatocellular adenoma from hepatocellular carcinoma with and without cirrhosis using E-cadherin and matrix metalloproteinase immunohistochemistry. Mod Pathol. Aug 2009;22(8):1113-20. [Medline].
Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. Nov 2008;132(11):1723-8. [Medline].
Tatrai P, Somoracz A, Batmunkh E, et al. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions. Am J Surg Pathol. Jun 2009;33(6):874-85. [Medline].
Ahmad I, Iyer A, Marginean CE, et al. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma. Hum Pathol. May 2009;40(5):726-34. [Medline].
Ishak KG. Benign tumors and pseudotumors of the liver. Appl Pathol. 1988;6(2):82-104. [Medline].
Bisceglia M, Gatta A, Tomezzoli A, Donataccio M. Multiple spontaneous liver cell adenomas of different types (liver adenomatosis). Adv Anat Pathol. May 2009;16(3):172-9. [Medline].
Geller S, Petrovic L. Benign tumors and tumor-like conditions. Biopsy Interpretation of the Liver. 3rd ed. Philadelphia, Pa: Williams and Wilkins.; 2003:281-304.
Gyorffy EJ, Bredfeldt JE, Black WC. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med. Mar 15 1989;110(6):489-90. [Medline].
Terkivatan T, de Wilt JH, de Man RA, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg. Sep 2001;136(9):1033-8. [Medline].
Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol. Mar 2009;16(3):640-8. [Medline].
Cho SW, Marsh JW, Steel J, et al. Surgical management of hepatocellular adenoma: take it or leave it?. Ann Surg Oncol. Oct 2008;15(10):2795-803. [Medline].
Selby R, Starzl TE, Ynis E, et al. Liver transplantation for type 1 and type glycogen storage disease. Eur J Pediatr. 1993;152:S71-76.
Santambrogio R, Marconi AM, Ceretti AP, et al. Liver transplantation for spontaneous intrapartum rupture of a hepatic adenoma. Obstet Gynecol. Feb 2009;113(2 pt 2):508-10. [Medline].
van Vledder MG, van Aalten SM, Terkivatan T, et al. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J Vasc Interv Radiol. Jun 2011;22(6):787-93. [Medline].
Ryan IP, Havel RJ, Laros RK Jr. Three consecutive pregnancies in a patient with glycogen storage disease type IA (von Gierke's disease). Am J Obstet Gynecol. Jun 1994;170(6):1687-90; discussion 1690-1. [Medline].
Bioulac-Sage P, Laumonier H, Cubel G, Rossi JZ, Balabaud C. Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins. Liver Int. Jan 2010;30(1):149-54. [Medline].
Cai YR, Gong L, Teng XY, Zhang HT, Wang CF, Wei GL, et al. Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma. World J Gastroenterol. Oct 7 2009;15(37):4695-708. [Medline].
Curvo-Semedo L, Brito JB, Seco MF, Costa JF, Marques CB, Caseiro-Alves F. The Hypointense Liver Lesion on T2-Weighted MR Images and What It Means. Radiographics. Nov 18 2009;[Medline].
De Carlis L, Pirotta V, Rondinara GF. Hepatic adenoma and focal nodular hyperplasia: diagnosis and criteria for treatment. Liver Transpl Surg. Mar 1997;3(2):160-5. [Medline].
Jang HJ, Yu H, Kim TK. Contrast-enhanced ultrasound in the detection and characterization of liver tumors. Cancer Imaging. Nov 6 2009;9:96-103. [Medline].
Lee RG. Neoplasms and other masses: Benign hepatocellular tumors. In: Diagnostic Liver Pathology. St. Louis, Mo:. Mosby-Yearbook;1994:422-430.
Mergo PJ, Ros PR. Benign lesions of the liver. Radiol Clin North Am. Mar 1998;36(2):319-31. [Medline].
Mortele KJ, Ros PR. Benign liver neoplasms. Clin Liver Dis. Feb 2002;6(1):119-45.
Reddy KR, Schiff ER. Approach to a liver mass. Semin Liver Dis. Nov 1993;13(4):423-35. [Medline].
van der Sluis FJ, Bosch JL, Terkivatan T, et al. Hepatocellular adenoma: cost-effectiveness of different treatment strategies. Radiology. Sep 2009;252(3):737-46. [Medline].
Weimann A, Ringe B, Klempnauer J. Benign liver tumors: differential diagnosis and indications for surgery. World J Surg. Nov-Dec 1997;21(9):983-90; discussion 990-1. [Medline].

